Table 5. PTX–siRNA Co-delivery Platforms in Cancer Therapya.
| nanovehicle | cancer type | cell line | target gene | size (nm) | zeta potential (mV) | encapsulation efficiency (EE) (%) | remarks | ref |
|---|---|---|---|---|---|---|---|---|
| solid lipid NPs | cervical cancer | HeLa cells | Bcl-2 | 180 | +22.2 to +48.16 | 97–98 | down-regulation of Bcl-2, and induction of apoptosis | (331) |
| liposome | melanoma | B16F10 cells | Bcl-2 | 136 | 34.5 | 94 (siRNA) | down-regulation of Bcl-2, and inhibition of growth and proliferation | (332) |
| 91.2 (PTX) | ||||||||
| lipid NPs | breast cancer | human triple-negative breast cancer MDA-MB-231 cells | elF4E | 10–60 | reversal of PTX resistance and induction of apoptosis | (333) | ||
| polymeric NPs | cervical cancer | HeLa cells | E7 | 100–1000 | –14.4 to −30 | 88.4 (siRNA) | effective delivery into cancer cells, enhanced accumulation of siRNA and PTX in cancer cells, down-regulation of E7 and suppressing cancer proliferation and malignancy | (334) |
| 90.2 (PTX) | ||||||||
| liposome | ovarian cancer | HeyA8-MDR cells | KSP | 150.7 | 12.1 | high cellular uptake, down-regulation of KSP, and more inhibitory effect on cancer cells compared to PTX alone | (335) | |
| micelle | breast cancer | MCF-7 | MDR1 | 171.6 | –22.52 | 93.92 | protection of siRNA against degradation by macrophages, down-regulation of MDR1 and suppressing tumor volume | (336) |
| micelle | breast cancer | MDA-MB-231 cells | AURKA | 135 | +14 | 86 | delivering cargo in an HA-receptor mediated endocytosis, and high antitumor activity | (337) |
| polymeric NPs | breast cancer | mouse breast cancer cell lines 4T1 | twist | 80–140 | +16 to +36 | 92.79 | suppressing metastasis of cancer cells via down-regulation of twist | (337) |
| polymeric NPs | ovarian cancer | MDR ovarian cancer cell lines SKOV3TR | MDR1 | 173.3 | –22.5 | inhibiting expressions and activities of P-gp and MDR1, and suppressing PTX resistance | (338) | |
| micelle | ovarian cancer | human ovarian adenocarcinoma resistant cell line, SKOV3-tr PXL resistant cells | survivin | 25 | 50 (siRNA) | down-regulation of survivin, and exerting antitumor activity | (339) | |
| 90 (PTX) | ||||||||
| micelle | liver cancer | human hepatocellular carcinoma (HCC) HepG2 cell | Bcl-2 | 394.3–427 | +22 | high cellular uptake, exerting antitumor activity and inhibition of Bcl-2 expression | (340) | |
| polymeric NPs | breast cancer | human breast cancer MCF-7 cells | VEGF | 120.48 | +47.60 | suppressing tumor growth for in vitro and in vivo | (341) |
a
NP: Nanoparticles.